Janssens, Peter
Jouret, François
Bammens, Bert
Liebau, Max C. http://orcid.org/0000-0003-0494-9080
Schaefer, Franz
Dandurand, Ann
Perrone, Ronald D.
Müller, Roman-Ulrich http://orcid.org/0000-0001-6910-0745
Pao, Christina S.
Mekahli, Djalila
Article History
Received: 23 July 2019
Accepted: 21 February 2020
First Online: 9 March 2020
Competing interests
: P.J. has nothing to disclose. F.J. has received financial support from Otsuka to attend scientific meetings and advisory boards. B.B. has received research support from Amgen, Astellas, Novartis, Otsuka, and Roche, speaker fees from Baxter, and support to attend advisory boards from Novartis and Otsuka. M.C.L. has received honoraria for scientific lectures from Pfizer and is an advisory board member for Otsuka as a representative of the University Hospital of Cologne. F.S., represented by Heidelberg University Hospital, received an educational grant from Otsuka and participated in advisory boards. A.D. and C.S.P. are employees of Otsuka. R.D.P. (represented by Tufts Medical Center) was a member of the advisory committee that advised Otsuka for both the TEMPO and REPRISE studies; he has received research support for clinical trials from Otsuka, Kadmon, the US Dept. of Defense, and Sanofi; and presently serves as an advisor to Sanofi for the STAGED-PKD trial. Additionally, he serves as an advisor to Palladio Biosciences and Vertex, has received travel expenses and honoraria from Otsuka, Spain for scientific lecture; and is section editor for UpToDate Wolters Kluwer. R.-U.M. received honoraria for scientific lectures and counseling from Otsuka and Thermo Fisher Scientific. The Dept. 2 of Internal Medicine Cologne was supported by research funding from Otsuka. D.M., represented by University Hospitals Leuven and KU Leuven University, received an educational grant from Otsuka and participated in an advisory board.